Epoch Investment Partners Inc. Sells 166,411 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Epoch Investment Partners Inc. lowered its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 82.3% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 35,856 shares of the specialty pharmaceutical company’s stock after selling 166,411 shares during the period. Epoch Investment Partners Inc. owned about 0.07% of Supernus Pharmaceuticals worth $959,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of SUPN. Fidelis Capital Partners LLC acquired a new stake in shares of Supernus Pharmaceuticals during the first quarter valued at about $33,000. Quadrant Capital Group LLC boosted its position in Supernus Pharmaceuticals by 1,117.6% during the 4th quarter. Quadrant Capital Group LLC now owns 1,449 shares of the specialty pharmaceutical company’s stock worth $42,000 after buying an additional 1,330 shares during the period. EntryPoint Capital LLC bought a new stake in Supernus Pharmaceuticals during the 1st quarter worth approximately $43,000. Meeder Asset Management Inc. bought a new stake in Supernus Pharmaceuticals during the 2nd quarter worth approximately $47,000. Finally, Innealta Capital LLC acquired a new position in Supernus Pharmaceuticals in the 2nd quarter valued at approximately $51,000.

Wall Street Analysts Forecast Growth

SUPN has been the topic of several analyst reports. Piper Sandler cut shares of Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $41.00 to $36.00 in a research note on Wednesday, September 11th. StockNews.com raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th.

Supernus Pharmaceuticals Price Performance

Shares of SUPN stock opened at $31.42 on Tuesday. Supernus Pharmaceuticals, Inc. has a one year low of $21.99 and a one year high of $35.44. The business’s 50 day simple moving average is $32.18 and its 200 day simple moving average is $30.45. The stock has a market capitalization of $1.73 billion, a PE ratio of -108.34 and a beta of 0.88.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $0.36 earnings per share for the quarter, missing the consensus estimate of $0.39 by ($0.03). The firm had revenue of $168.30 million for the quarter, compared to analyst estimates of $148.83 million. Supernus Pharmaceuticals had a return on equity of 0.56% and a net margin of 0.83%. The company’s quarterly revenue was up 24.1% compared to the same quarter last year. During the same quarter last year, the company earned ($0.02) earnings per share. As a group, research analysts expect that Supernus Pharmaceuticals, Inc. will post 1.53 earnings per share for the current year.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.